Immunological parameters in the sera of patients with atopic dermatitis and airborne allergy treated with allergy vaccines

Acta Dermatovenerologica Croatica

Volumn 14, Issue 1, 2006, Pages 8-20

  Czarnecka Operacz, Magdalena ^a   Silny, Wojciech ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Antigen specific IgE; Atopic dermatitis; Cytokines; Specific immunotherapy; Total IgE

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; VACCINE;

ADOLESCENT; ADULT; AIRBORNE INFECTION; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MALE;

ADOLESCENT; ADULT; ALLERGENS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYTOKINES; DERMATITIS, ATOPIC; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; POLLEN; PYROGLYPHIDAE; RESPIRATORY HYPERSENSITIVITY;

EID: 33646055186     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Washio Y, Kato A, et al. Serological study of working mechanisms of immunotherapy for children with perennial allergic rhinitis. Arch Otolaryngol Head Neck Surg 1998;86:147-158.
2. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Washio Y, Kato A, et al. Ten year follow-up study of allergen-specific immunoglobulin E and immunoglobulin G4, soluble interleukin 2 receptor, interleukin 4, soluble intercellulator adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in serum of patients on immunotherapy for perennial allergic rhinitis. Scand J Immunol 1998;47:167-178.
3. Ohashi Y, Nakai Y, Kihara S. House dust mite-specific IgE, IgE1 and IgG4 antibodies in patients with perennial rhinitis. Ann Otol Rhinol Laryngol 1987;96:434-437.
4. Ohashi Y, Nakai Y, Okamoto H, Ohno Y, Sakamoto H, Tanaka A, et al. Significant correlation between symptom score and IgG4 antibody titer following long-term immunotherapy for perennial allergic rhinitis. Ann Otol Rhinol Laryngol 1997;106:483-489.
5. Tsal LC, Hung MW, Tang RB. Changes of serum - specific IgE antibody titer during hyposensitization in mite-sensitive asthmatic children. J Asthma 1990;27,95-100.
6. Cltyon WF, Reisman RE, Georgitis JW, Wypych JI, Arbesman CE. Effect of prolonged venom immunotherapy on serum venom specific IgE and IgG. Clin Allergy 1983;13:301-307.
7. Kato S, Nakai Y, Chashi Y, Kato M. RAST in diagnosis and therapy of allergic rhinitis. Acta Otolaryngol 1991;486:209-216.
8. Hanifin JM. Atopic dermatitis. J Allergy Clin Immunol 1984;73:211-226.
9. Kapp A, Wokalek H, Schöpf E. Involvement of complement in psoriasis and atopic dermatitis - Measurement of C3a and C5a, C3, C4 and C1 inactivator. Arch Dermatol Res 1985;277:359-361.
10. Kapp A, Kemper A, Schöpf E. Detection of circulating immune complexes in patients with atopic dermatitis and psoriasis. Acta Derm Venereol 1986;66:121-126.
11. Kapp A, Schöpf E. Cellular reactivity of polymorphonuclear leukocytes in psoriasis and atopic dermatitis. Acta Derm Venereol 1986;66:285-289.
12. Leung DYM, Geha RS. Immunoregulatory abnormalities in atopic dermatitis. Clin Rev Allergy 1986;4:67-86.
13. Schöpf E, Kopp A, Kim CW. T-cell function in atopic dermatitis - Controlled examination of concanavalin A - dose - response relations in cultured lymphocytes. Arch Dermatol Res 1978;262:37-44.
14. Kopp A. Cytokines in atopic dermatitis In: Ruzicka T, Ring J, Przybilla B, editors. Handbook of eczema. Berlin:Springer, 1991.
15. Grewe M, Bruijnzeel-Koomen C, Schöpf E, Thepen T, Langeveld-Widschut AG, Ruzicka T, et al. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 1998;18:359-361.
16. Ebner C. Immunological mechanisms operative in allergen specific immunotherapy. Int. Arch. Allergy Immunol 1999;119:1-5.
17. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Washio Y, Nakai Y. Allergen specific immunotherapy for allegic rhinitis: A new insight into its clinical efficacy and mechanism. Acta Otolaryngol 1998;538:178-190.
18. Jutel M. Mechanisms of specific immunotherapy. Int Rev Allergol Clin Immunol 1999;5:179-183.
19. Silny W, Czarnecka-Operacz M, Gołȩbka E, Silny P. W-AZS a new scoring index for patients with atopic dermatitis. Przegl Dermatol 1999;86:215-222.
20. Czarnecka-Operacz M, Bator-Wegner M, Silny W. Atopy patch test reaction to air-borne allergens in the diagnosis of atopic dermatitis. Acta Dermatovenereol Croat 2005;13:3-16.
21. O'Loughlin S, Diaz-Perez JL, Gleich GJ, Winkelmann RK. Serum IgE in dermatitis and dermatosis Arch Dermatol 1977;113:309-312.
22. Okrasiński H, Okrasińska K. Zachowanie siȩ IgE w surowicy krwi w atopowym zapaleniu skóry. Przegl Dermatol 1978;65:149-153.
23. Przyk K, Ruszczak Z, Czarnecki M. Odczynowość humoralna u chorych na atopowe zapalenie skóry. Zachowanie siȩ IgE w surowicy krwi chorych na atopowe zapalenie skóry. Przegl Dermatol 1980;67:557-561.
24. Wittig HJ, Belloit I, de Fillippi I, Royal G. Age related serum immunoglobulin E levels in healthy subjects and patients with allergic diseases. J Allergy Clin Immunol 1980;66:305-307.
25. Wüthrich B, Kopper E, Virhow Ch. IgE Bestimmung bei Neurodermitis und anderen Dermatosen. Hautartzt 1973;24:381-385.
26. Malling HJ, Weeke B. Immunotherapy. Position papers. Allergy 1993;48:22-28.
27. Ortolani C, Paterello EA, Incorovaia C, Ispano M, Farioli L, Zara C, et al. A double blind placebo controlled study of immunotherapy with an alginate-conjugated extract of Parietaria Judaica in patients with Parietaria hay fever. Allergy 1994;49:13-21.
28. Skibic D, Jutel M, Fishier H. Ultrarush immunotherapy with hymenoptera venoms. Allergologie 1996;16:123-129.
29. Pacor ML, Biasi D, Malekina T. The efficacy of long-term specific immunotherapy for Dermatophagoides pteronyssinus in patients with atopic dermatitis. Recenti Prog Med 1994;85:273-277.
30. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allerg 1992;22:440-446.
31. Kapp A, Neuner P, Krutmann J, Luger TA, Schopf E. Production of interleukin-2 by mononuclear cells in vitro in patients with atopic dermatitis and psoriasis. Comparison with serum interleukin-2 receptor levels. Acta Derm Venereol 1991;71:403-406.
32. Kapp A, Gillizer R, Kichner H, Schopf E. Production of interferon and lymphoproliferative responses in whole blood cultures derived from patients with atopic dermatitis. Arch Dermatol Res 1987;27:55-58.
33. Leung DYM, Geha RS. Immunoregulatory abnormalities in atopic dermatitis. Clin Rev Allergy 1986;4:67-86.
34. Schöpf E, Kapp A, Kim CW. T-cell function in atopic dermatitis. Controlled examination of concanavalin. A dose-response relations in cultured lymphocytes. Arch Dermatol Rev 1978;262:37-44.
35. Kapp A, Piskorski A, Schöpf E. Elevated levels of interleukin-2 receptor in sera of patients with atopic dermatitis and psoriasis. Br J Dermatol 1988;119:707-710.
36. Zachary CB, Mc Donald DM. Quantitive analysis of T-lymphocyte subsets in atopic eczema, using monoclonal antibodies and flow cytometry. Br J Dermatol 1983;108:411-422.
37. Thestrup-Pedersen K, Schade Larsen C, Kristensen M, Zachariae C. Interleukin-1 release from peripheral blood monocytes and soluble interleukin-2 and CD8 receptors in serum from patients with atopic dermatitis. Acta Derm Venereol 1990;70:395-399.
38. Kasamatsu M, Tsuji T, Miura M. A method for the quantification of interleukin-4 in serum (sandwich ELISA) and IL-4 levels in patients with atopic dermatitis. Arerugi 1993;42:878-882.
39. Takahashi T, Sasaki Y, Hama K, Furue M, Ishibashi Y. Production of IL-4, IL-2, IFN-α by peripheral blood mononuclear cells of patients with atopic dermatitis. J Dermatol Sci 1992;3:172-180.
40. Silny W, Czarnecka-Operacz M. Specific immunotherapy in the treatment of patients with atopic dermatitis. Fr Alergol 1999;56(Numero special):87-88.
41. Silny W, Czarnecka-Operacz M. Specific immunotherapy in the treatment of atopic dermatitis. Alergia Astma Immunol 1999;4(suppl.2):85-87.
42. Silny W, Czarnecka-Operacz M. Possible application of specific immunotherapy in the treatment of atopic dermatitis-modulation of immune response.Alergia Astma Immunol 2000;5(suppl.1):31-34.
43. Czarnecka-Operacz M, Silny W. Specific immunotherapy in selected cases of atopic dermatitis.Przewodnik Lekarza 2001;3:118-121.
44. Silny W, Czarnecka-Operacz M. Atopic dermatitis - New methods of treatment. Przewodnik Lekarza 2002;3:48-56.